CHOLANGIOCARCINOMA MARKET ANALYSIS

Cholangiocarcinoma Market, By Cancer Type [Extrahepatic Cholangiocarcinoma (Perihilar, Distal), Intrahepatic Cholangiocarcinoma], By Therapy Type [Targeted Drug Therapy (Pemigatinib, Ivosidenib, Futibatinib, Infigratinib), Chemotherapy (5-Fluorouracil, Gemcitabine, Cisplatin, Capecitabine, Oxaliplatin), Immunotherapy (Pembrolizumab, and Others), and Others (Pain Medications and Others)], By Route of Administration (Oral, Subcutaneous, and Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-commerce), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Oct 2023
Code : CMI4435
Pages :156
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global Cholangiocarcinoma Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global cholangiocarcinoma market over the forecast period. North America is estimated to hold 59.1% of the market share in 2023. North America cholangiocarcinoma market is expected to witness significant growth in the near future, owing to approval of new drugs in the market. For instance, in May 2021, the U.S. FDA granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics, Inc., a biotechnology company), a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa